LTR Pharma Executes Definitive US Distribution Agreement With Shed Holdings for ROXUS, Shares Up 11%

MT Newswires Live
07/17

LTR Pharma (ASX:LTP) executed a definitive telehealth distribution agreement with Shed Holdings, a US direct-to-consumer telehealth platform, converting a previously disclosed binding term sheet into a definitive commercial agreement for the planned US commercialization of ROXUS, according to a Friday Australian bourse filing.

The company said Shed has committed to support the delivery of not less than 150,000 ROXUS units during the first 12 months following commercial launch.

ROXUS is the company's fast-acting intranasal spray for the treatment of erectile dysfunction.

The company's shares rose 11% in recent Friday trade.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10